关键词
How to Cite
摘要
В статье рассматриваются предварительные результаты комплексного лечения больных местнораспространенным раком прямой кишки с предоперационной химиолучевой терапией (ХЛТ) и консолидирующей химиотерапией (ХТ). В исследование включено 89 больных со стадией опухолевого процесса T3(CRM+)-4N0-2M0. В группе А проводилась предоперационная ХЛТ в изодозе 56 Гр на фоне ХТ капецитабином 825 мг/м2 2 раза в сутки per os с консолидирующей ХТ (2 курса XELOX), в группе Б проводилось аналогичное лечение без консолидирующей ХТ. В группу А включено 49 пациентов, в группу Б - 40 пациентов. У 9 (18,4%) пациентов в группе А при контрольном обследовании диагностирован полный клинический ответ, что послужило причиной воздержания от хирургического лечения, и они взяты под динамическое наблюдение. У 9 из 40 (22,5%) прооперированных пациентов из группы А отмечен клинически значимый полный морфологический ответ в опухоли (ypT0N0). В контрольной группе Б полного клинического ответа не достигнуто ни у одного пациента...参考
Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 году // Вестник РОНЦ им. Н.Н. Блохина РАМН. - 2010. - № 3.
An X., Lin X., Wang F. et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis // Eur. J. Cancer. - 2013. - Vol. 49(4). - P. 843-851.
Capirci C., Valentini V., Cionini L. et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients // Int. J. Radiat. Oncol. Biol. Phys. - 2008. - Vol. 72. - № 1. - P. 99-107.
Chand M., Rasheed S., Heald R. et al. Adjuvant chemotherapy may improve disease-free survival in patients with mrEMVI-positive rectal cancer following chemoradiation // Colorectal Dis. - 2016.
Chang J., Ormerod M., Powles T. et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma // Cancer. - 2000. - Vol. 89 (11). - P 2145-2152.
Dellas K., Buller J., Görtz G. et al. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications // Ann Surg Oncol. - 2014. - Vol. 21(4). - P. 1352-1360.
Dellas K., Höhler T., Reese T. et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer // Radiat Oncol. - 2013. - Vol. 8. - P. 90.
Gamaleldin M., Church J., Stocchi L. et al. Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified? // Am J. Surg. - 2017. - Vol. 213(3). - P. 478-483.
Gao Y., Zhang X., An X. et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer // Strahlenther. Onkol. - 2014. - Vol. 190. - P. 158-164.
Garcia-Aguilar J., Smith D., Avila K. et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial // Ann Surg. - 2011. - Vol. 254. - P. 97-102.
Gollins S., Myint S., Susnerwala S. et al. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2) // Br. J. Cancer. - 2009. - Vol. 101(6). - P 924-934.
Habr-Gama A., Perez R., Sabbaga J. et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period // Dis Colon Rectum. - 2009. - Vol. 52. - P. 1927-1934.
Iles S., Gollins S., Susnerwala S. Irinotecan 5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study // Br. J. Cancer. - 2008 - Vol. 98(7). - P. 1210-1216.
Jalil O., Claydon L., Arulampalam T. Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer // J. Gastrointest Cancer. - 2015. - Vol. 46(3). - P. 219-236.
Jiaolin Z., Huizhong Q., Guole L., Yuchao L. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center // International Journal of Colorectal Disease. - 2016. - Vol. 31(6). - P. 1163-1168.
Jung K., Kim H., Park J. et al. Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients? // J Surg Oncol. - 2015. - Vol. 111(4). - P. 439-444.
Kennecke H., Berry S., Wong R. et al. Pre-operative beva-cizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial // Eur. J. Cancer. - 2012. - Vol. 48. - P. 37-45.
Kim N., Baik S., Seong J. et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival // Ann Surg. - 2006. - Vol. 244(6). - P. 1024-1030.
Kuo L., Liu M., Jian J. et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? // Ann Surg. Oncol. - 2007. - Vol. 14. - P 2766-2772.
Landry J., Feng Y., Prabhu R. et al. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplat-in, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 // Oncologist. - 2015. - Vol. 20(6). - P. 615-616.
Maas M., Nelemans P., Valentini V. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data // Lancet Oncol. - 2010. - Vol. 11. - № 9. - P. 835-844.
Martin S., Heneghan H., Winter D. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer // Br. J. Surg. - 2012. - Vol. 99. - № 7. - P. 918-928.
Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. // Lancet. - 1996. - Vol. 48(9042). - P. 1605-1610.
McCarthy K., Pearson K., Fulton R. et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer // Cochrane Database Syst Rev. - 2012. - Vol. 12. - CD008368.
Musio D., De Felice F., Bulzonetti N. et al. Neoadjuvant-intensified treatment for rectal cancer: time to change? // World J. Gastroenterol. - 2013. - Vol. 19(20). - P. 3052-3061.
National Cancer Comprehensive Network. Clinical practice guidelines in oncology: rectal cancer.v 2. - 2012. URL: http://www.nccn.org
Nogue M., Salud A., Vicente P. et al. Addition of beva-cizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study // Oncologist. - 2011. - Vol. 16. - P. 614-620.
Petersen S., Harling H., Kirkeby L. et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure // Cochrane Database Syst Rev. - 2012. - Vol. 3. - CD004078.
Quah H., Chou J., Gonen M. et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal Cancer patients after preoperative chemoradiation // Cancer. - 2008. - Vol. 113. - P. 57-64.
Roh M., Yothers G., O'Connell M. et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum // J. Clin. Oncol. - 2011. - abstr 3503.
Stewart B., Wild C. World Cancer Report // IARC Nonserial Publication, 2014. - 630 pages.
Sun Y, Chi P., Lin H. et al. Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemo-radiotherapy // Zhonghua Wei Chang Wai Ke Za Zhi. - 2016. - Vol. 19(4). - P. 436-441.
Tepper J., Wang A. Improving local control in rectal cancer: Radiation sensitizers or radiation dose? // J. Clin. Oncol. - 2010. - Vol. 28(10). - P. 1623-1624.
The Beyond TME Collaborative // Br J Surg. - 2013. - Vol. 100(8). - P. 1009-1014.
Zampino M., Magni E., Leonardi M. et al. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer // Int. J. Radiat. Oncol. Biol Phys. - 2009. - Vol. 75. - P. 421-427.
Wang C., Liang J., Tsai C. et al. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity // World J. Surg. Oncol. - 2014. - Vol. 2. - P. 329.
Wen B., Zhang L., Wang C. et al. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy // Radiat. Oncol. - 2015. - Vol. 10. - P. 124.
Wong R., Tandan V., De Silva S. et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma // Cochrane Database Syst Rev. - 2007. - Vol. (2). - CD002102.
Xu Z., Mohile S., Tejani M. et al. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal Cancer: An NCDB analysis // Cancer. - 2017. - Vol. 123(1). - P. 52-61.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017